Status:
COMPLETED
United States Pharmacovigilence Retapamulin-Prescribing
Lead Sponsor:
GlaxoSmithKline
Conditions:
Skin Infections, Bacterial
Eligibility:
All Genders
Brief Summary
Retapamulin, a topical pleuromutilin antibiotic, is the first in a new class of topical antibiotics approved for human use. In the United States (US), retapamulin is approved for the treatment of impe...
Detailed Description
The IHCIS is Health Insurance Portability and Accountability Act (HIPAA) compliant with encrypted member and provider identifiers; date of birth is restricted to year of birth. Based on year of birth ...
Eligibility Criteria
Inclusion
- The study population will consist of all 'eligible members' in the IHCIS database with a valid gender and age record who have at least 1 month enrolment and eligibility of pharmacy benefits.
Exclusion
- Membership in IHCIS without a valid gender or age record, enrolment less than 1 month, or ineligibility for pharmacy benefits will be excluded.
Key Trial Info
Start Date :
December 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2012
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT01153880
Start Date
December 1 2008
End Date
August 1 2012
Last Update
June 10 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.